BR112016025450A2 - moduladores de canais de íons e usos dos mesmos - Google Patents

moduladores de canais de íons e usos dos mesmos

Info

Publication number
BR112016025450A2
BR112016025450A2 BR112016025450A BR112016025450A BR112016025450A2 BR 112016025450 A2 BR112016025450 A2 BR 112016025450A2 BR 112016025450 A BR112016025450 A BR 112016025450A BR 112016025450 A BR112016025450 A BR 112016025450A BR 112016025450 A2 BR112016025450 A2 BR 112016025450A2
Authority
BR
Brazil
Prior art keywords
ion channel
channel modulators
methods
antibodies
polypeptides
Prior art date
Application number
BR112016025450A
Other languages
English (en)
Inventor
Dobson Claire
Jones Clare
Jan Snijder Harm
Button James
Linley John
Huang Ling
Groves Maria
Sridharan Sudharsan
A Williams Wendy
Shibata Yoko
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of BR112016025450A2 publication Critical patent/BR112016025450A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a invenção proporciona anticorpos que se ligam especificamente a um polipeptídeo p2x4 e modulam a atividade de canais de p2x4, polipeptídeos p2x4 recombinantes e métodos para geração de tais polipeptídeos, bem como composições e métodos para geração de anticorpos anti-p2x4, e métodos de uso de anticorpos para p2x4 para o tratamento da dor neuropática e outras indicações.
BR112016025450A 2014-05-02 2015-05-02 moduladores de canais de íons e usos dos mesmos BR112016025450A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461987929P 2014-05-02 2014-05-02
PCT/EP2015/059633 WO2015166105A2 (en) 2014-05-02 2015-05-02 Ion channel modulators and uses thereof

Publications (1)

Publication Number Publication Date
BR112016025450A2 true BR112016025450A2 (pt) 2017-12-12

Family

ID=53055033

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016025450A BR112016025450A2 (pt) 2014-05-02 2015-05-02 moduladores de canais de íons e usos dos mesmos

Country Status (8)

Country Link
US (2) US10654926B2 (pt)
EP (2) EP3137501B1 (pt)
JP (2) JP2017515473A (pt)
AU (1) AU2015254558B2 (pt)
BR (1) BR112016025450A2 (pt)
CA (1) CA2946669A1 (pt)
ES (1) ES2899754T3 (pt)
WO (1) WO2015166105A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11266690B2 (en) * 2018-02-01 2022-03-08 Nanjing Iaso Biotherapeutics Co., Ltd. Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
WO2020186158A2 (en) * 2019-03-13 2020-09-17 Ulmert Hans David Staffan Prame binding molecules and uses thereof
US20220298238A1 (en) * 2019-08-23 2022-09-22 Unm Rainforest Innovations Non-opioid compositions and therapies for pain management
CA3161825A1 (en) * 2019-11-18 2021-05-27 Janssen Biotech, Inc. Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
CA3195817A1 (en) * 2020-10-16 2022-04-21 Brian Scott GARRISON Chimeric receptors and methods of use thereof
CN114685657A (zh) * 2020-12-31 2022-07-01 康诺亚生物医药科技（成都）有限公司 一种功能增强型抗体阻断剂的开发及其应用
WO2023114962A1 (en) * 2021-12-16 2023-06-22 Unm Rainforest Innovations Humanized non-opioid composition and therapies for pain management

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6242216B1 (en) * 1997-11-14 2001-06-05 Abbott Laboratories Nucleic acids encoding a functional human purinoreceptor P2X2 and P2X4, and methods of production and use thereof
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AUPR201500A0 (en) * 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
CA2444161A1 (en) 2003-10-01 2005-04-01 Japan Health Sciences Foundation A screening method of drug for treatment of neuropathic pain
WO2005107804A1 (ja) * 2004-05-06 2005-11-17 Ono Pharmaceutical Co., Ltd. 呼吸器疾患治療剤
DK2397480T3 (da) 2009-02-16 2013-09-02 Nippon Chemiphar Co Diazepindionderivat
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування

Also Published As

Publication number Publication date
JP2017515473A (ja) 2017-06-15
EP3137501B1 (en) 2021-09-29
US10654926B2 (en) 2020-05-19
WO2015166105A2 (en) 2015-11-05
JP2020018307A (ja) 2020-02-06
EP4001310A2 (en) 2022-05-25
EP3137501A2 (en) 2017-03-08
US20200247885A1 (en) 2020-08-06
WO2015166105A3 (en) 2015-12-30
AU2015254558A1 (en) 2016-12-08
US20170166634A1 (en) 2017-06-15
AU2015254558B2 (en) 2021-02-25
ES2899754T3 (es) 2022-03-14
CA2946669A1 (en) 2015-11-05
EP4001310A3 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
BR112016025450A2 (pt) moduladores de canais de íons e usos dos mesmos
CY1123853T1 (el) Ρυθμιστες nrf2
CY1124761T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
CY1123031T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
BR112015031073A2 (pt) inibidores bicíclicos de bromodomínio
MX2015013103A (es) Métodos y composiciones para control de malezas.
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
SA519402159B1 (ar) بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
PH12019501079A1 (en) Magl inhibitors
BR112016029076A8 (pt) Modulação de atividade de complemento
EA202090296A1 (ru) Спироциклические соединения и способы их получения и применения
EA201790922A1 (ru) Ингибиторы бромодомена
GT201700063A (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos
CL2019002251A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
BR112017018940A2 (pt) anticorpos sítio-específicos projetados e métodos de uso
MX2019002190A (es) Uso de pridopidina para tratar distonías.
EA202090312A1 (ru) Спироциклические соединения и способы их получения и применения
EA201792262A1 (ru) Пироглутамат вортиоксетина
BR112016022879A2 (pt) ativadores de histona acetiltransferase e usos dos mesmos
EA201691269A1 (ru) Дерматологическая композиция на основе экстрактов водорослей и листа оливы
BR112019008606A2 (pt) inibidores de interações de mtor-deptor e métodos de uso dos mesmos
CO2020013557A2 (es) Variantes de lfa3 y composiciones y usos de las mismas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.